Teclistamab, Talquetamab, and Elranatamab: Response Rates and Data
May 10, 2024 ·
6m 2s
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
Dr. Sridevi Rajeeve discusses the unprecedented response rates in patients treated with teclistamab, talquetamab, and elranatamab, as well as their clinical trial data.
Information
| Author | cancerGRACE |
| Website | - |
| Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
